Table 5.
Patients with CVD, retinopathy and CKD stage ≥ 3 at baseline and at the end of the follow up according to treatment of T2D at baseline (seven missing patients excluded from the analysis)
| All | No treatment 148 (53.6%) |
Metformin 84 (29.1%) |
Secretagogues 50 (17.3%) |
p value | |
|---|---|---|---|---|---|
| Baseline CV disease (n; %) | 44 | 26; 17.6 | 9; 10.7 | 9; 18.0 | ns |
| Follow up CV disease (n; %) | 18 | 8; 5.4 | 3; 3.6 | 7; 14.0 | 0.04 |
| Baseline any retinopathy (n; %) | 7 | 3; 2.0 | 0; 0 | 4; 8.0 | 0.015 |
| Follow up any retinopathy (n; %) | 13 | 7; 4.7 | 0; 0 | 6; 12.0 | 0.007 |
| Baseline CKD stage ≥ 3 | 38 | 21; 14.2 | 9; 10.7 | 8; 16.0 | ns |
| Follow up CKD stage ≥ 3 | 17 | 9; 6.1 | 2; 2.4 | 6; 12.0 | ns |